Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Cessation of coverage

Hotel Property Investments
3:27pm
January 16, 2025
Following a review of our research universe, we discontinue coverage of Hotel Property Investments (HPI AU). Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Strolling ahead

Baby Bunting Group
3:27pm
January 15, 2025
BBN has provided a trading update for 1H25 performance, with unaudited pro-forma NPAT of $4.8m up 37% on 1H24 and has re-affirmed FY25 guidance. Pleasingly, LFL sales accelerated to +4.5% in the 2Q, from the 0.6% increase reported at the AGM YTD to October. This reflects a strong trading period in November and December, likely driven by the refined go-to-market strategy. We have made no changes to our forecasts and valuation and as such retained our HOLD recommendation.

Model update

Monadelphous Group
3:27pm
January 14, 2025
We have updated our forecasts ahead of the February reporting season to align with the AGM guidance for 1H revenue to be up slightly YoY and FY25 revenue to grow high single digits. This sees our EPS forecast rise by 3.6% in FY25 with similar positive EPS revisions in FY26 and FY27 (~4.0%). The effect of slightly higher earnings sees our target price increase from $13.80 to $14.28.

Cessation of coverage

Vulcan Steel
3:27pm
January 14, 2025
Following a review of our research universe, we discontinue coverage of Vulcan Steel (VSL AU). Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Cessation of coverage

DGL Group
3:27pm
January 14, 2025
Following a review of our research universe, we discontinue coverage of DGL Group (DGL AU). Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Cessation of coverage

Cedar Woods Properties
3:27pm
January 14, 2025
Following a review of our research universe, we discontinue coverage of Cedar Woods Properties (CWP AU). Our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Risk still outweighs reward

The Star Entertainment Group
3:27pm
January 14, 2025
Last week, SGR released a market update on its liquidity position prompting us to revise our model to reflect this, alongside insights post its AGM. Despite some incremental updates, we view the risk-reward payoff as unfavorable due to: a) Lack of near-term funding options, b) Limited support from state bodies, c) Uneven playing field in the domestic venue-based gaming sector, d) Risk of further dilutive equity raises, and e) Persistent weakness in player behavior, driven by mandatory carded play (MCP), cost-of-living and competitive pressures. We maintain our Reduce recommendation, lowering our 12-month target price to $0.12 (from $0.22). This is reflective of our view around further potential downside risk due to funding challenges and SGR’s ability to remain a going concern. We expect a quarterly update in late January and interim result on the 28th of February.

Model adjustments

Atlas Arteria
3:27pm
January 9, 2025
The proposed temporary supplemental company income tax in France was not legislated prior to the end of 2024 due to a no-confidence vote in the previous prime minister (relates to ALX’s APRR investment). We assume the budget bill will be passed during 2025, impacting APRR’s tax expense in FY25-26F instead of FY24-25F previously, with the relevant tax paid spread across FY25-27F instead of FY25-26F. Our modelling has also been revised for spot AUDUSD and AUDEUR, with the c.8% reduction in AUDUSD since our last update in October particularly notable (supporting translation of USD equity valuations and Chicago Skyway forecast distributions). With revised forecasts we now believe ALX’s annual distribution of 40 cps can be sustained across FY25-26F instead of needing to be reduced. This implies a cash yield of 8.4% at current prices. 12 month target price $4.61 per share (-3 cps from previously). Standalone valuation (ex IFM takeover potential) of $4.32 per share. HOLD retained.

Downgrade to CY24 although solid growth for CY25

Avita Medical
3:27pm
January 8, 2025
AVH has finished the year with a miss on the 4Q revenue which was disappointing and caps off a year where quarterly sales forecasting has proved difficult. However new product approvals and good sales momentum sets the scene for a solid CY25. We have adjusted our forecasts to reflect revised guidance resulting in a 4.3% downgrade to our target price which now sits at A$4.36 (was $4.56). We have maintained our Add rating although acknowledge the revenue miss has unsettled investors and will now need a few solid quarters to regain market confidence.

December 2024 Trading activity

Aust Securities Exchange
3:27pm
January 7, 2025
ASX has released its monthly trading activity report for December 2024. It was an improved trading month overall for ASX, with higher cash markets activity (+7% on the pcp) and stronger futures volumes being the main take away. We increase our FY25-FY27F EPS by ~2% factoring in the recent trading activity report, with the key driver being the improved cash markets activity and strong Futures activity over the half. Our price target increases to A$66.80 (from A$62.90) on the above changes and DCF roll-forward. Given the < 10% TSR upside to our price target we maintain our Hold recommendation.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more